Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | KAT7 | O95251 | 15/20 | 0.49 |
| ▸ | KAT6A | Q92794 | 15/20 | 0.49 |
| ▸ | KAT6B | Q8WYB5 | 11/20 | 0.48 |
| ▸ | KAT5 | Q92993 | 8/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 8/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31516625 | 0.91 | KAT7 (0.48) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31172712 | 0.90 | KAT7 (0.46) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31691246 | 0.90 | ALPL (0.43) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31691394 | 0.89 | KAT7 (0.44) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31516641 | 0.88 | KAT7 (0.46) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31516707 | 0.88 | KAT7 (0.48) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31516663 | 0.88 | KAT7 (0.45) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31691386 | 0.88 | ALPL (0.41) | HDAC1HDAC6KAT7KAT6AKAT6B | |
| SCHEMBL31516645 | 0.88 | KAT7 (0.46) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31691431 | 0.87 | KAT7 (0.45) | HDAC1HDAC6KAT7KAT6AKAT6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122152-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT7 | HDAC1 11/4885HDAC6 8/4885KAT7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.